Michelle Dipp, MD, Ph.D, CEO and cofounder of OvaScience,in early April 2012, had received a buyout offer from PG Ventures, a private equity firm interested in acquiring the innovative fertility treatments business.
OvaScience Case Study Solution
The entity’s first fruitful fertility treatment, AUGMENT (Autologous Germ-line Mitochondrial Energy Transfer), does have the capacity to ameliorate the egg quality, increase the success of IVF cycles, and also reduce the incidence of several births. (i.e., twins, triplets).
OvaScience had been an embedded part since 2011, and AUGMENT had not yet reached the market. Dipp and her partners had high expectations for the success of the impact the underlying technology could have on millions of infertility cases around the world and AUGMENT. How fast might her team and Dipp grow OvaScience? Would they possess the resources? Dipp considered the best method to develop out OvaScience's business model and possibility of AUGMENTS potential outweighed the PG Ventures.
PUBLICATION DATE: September 05, 2014 PRODUCT #: 815058-HCC-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
Pedigree Case Solution
Amazon.com (A)
Codensa: Easy Credit for All, Spanish Version
Maruti Suzuki India Limited: Sustaining Profitability
Malaysia’s Genting: Gambling on the West
Solving the Problems of New Product Forecasting
edX: Strategies for Higher Education
Utilis: Designing, Producing, and Selling Rapid Deployment Shelters for a Troubled World
How Government Shaped the American Diet
Trench Town Rock: The Creation of Jamaica’s Music Industry
